Galectin Therapeutics (GALT) Gains from Investment Securities (2010 - 2026)
Galectin Therapeutics' quarterly Gains from Investment Securities came in at $211583.0 in Q1 2026, up 746.33% year-on-year from $25000.0 in Q1 2025, and up 138.86% quarter-over-quarter from $88579.0 in Q4 2025.
Galectin Therapeutics has reported Gains from Investment Securities for 16 years, with the latest figure at $211583.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 746.33% year-over-year to $211583.0; the trailing twelve-month figure through Mar 2026 stood at $211583.0 (down 66.19% YoY), and the FY2025 full-year result was $6.6 million, up 378.7% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $211583.0, up from $88579.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $5.6 million in Q2 2022, with the low at -$229000.0 in Q1 2022.
- Average Gains from Investment Securities over 5 years is $539316.4, with a median of $153288.0 recorded in 2024.
- Peak annual rise in Gains from Investment Securities reached 3182.3% in 2022, while the deepest fall reached 1480.52% in 2022.
- Tracing GALT's Gains from Investment Securities over 5 years: stood at $945000.0 in 2022, then sank by 83.46% to $156345.0 in 2023, then surged by 92.17% to $300445.0 in 2024, then sank by 70.52% to $88579.0 in 2025, then soared by 138.86% to $211583.0 in 2026.
- The last three Gains from Investment Securities figures came in at $211583.0 (Q1 2026), $88579.0 (Q4 2025), and $177334.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 211,583.00 |
| Mar 31, 2026 | 211,583.00 |
| Dec 31, 2025 | 88,579.00 |
| Dec 31, 2025 | 88,579.00 |
| Sep 30, 2025 | 177,334.00 |
| Sep 30, 2025 | 177,334.00 |
| Jun 30, 2025 | 88,579.00 |
| Jun 30, 2025 | 88,579.00 |
| Mar 31, 2025 | 25,000.00 |
| Mar 31, 2025 | 25,000.00 |
| Dec 31, 2024 | 300,445.00 |
| Dec 31, 2024 | 300,445.00 |
| Sep 30, 2024 | 153,288.00 |
| Sep 30, 2024 | 153,288.00 |
| Jun 30, 2024 | 300,445.00 |
| Jun 30, 2024 | 300,445.00 |
| Mar 31, 2024 | 153,288.00 |
| Mar 31, 2024 | 153,288.00 |
| Dec 31, 2023 | 156,345.00 |
| Dec 31, 2023 | 156,345.00 |
| Sep 30, 2023 | 75,529.00 |
| Sep 30, 2023 | 75,529.00 |
| Jun 30, 2023 | 156,345.00 |
| Jun 30, 2023 | 156,345.00 |
| Mar 31, 2023 | 75,529.00 |
| Mar 31, 2023 | 75,529.00 |
| Dec 31, 2022 | -277,000.00 |
| Dec 31, 2022 | -277,000.00 |
| Sep 30, 2022 | 195,000.00 |
| Sep 30, 2022 | 195,000.00 |
| Jun 30, 2022 | 195,000.00 |
| Jun 30, 2022 | 195,000.00 |
| Mar 31, 2022 | 745,000.00 |
| Mar 31, 2022 | 745,000.00 |
| Dec 31, 2021 | 532,447.00 |
| Dec 31, 2021 | 532,447.00 |
| Sep 30, 2021 | 1.19 Mn |
| Sep 30, 2021 | 1.19 Mn |
| Jun 30, 2021 | 172,000.00 |
| Jun 30, 2021 | 172,000.00 |
| Mar 31, 2021 | 16,588.00 |
| Mar 31, 2021 | 16,588.00 |
| Dec 31, 2020 | 39,792.00 |
| Dec 31, 2020 | 39,792.00 |
| Dec 31, 2019 | 3.00 Mn |
| Dec 31, 2019 | 3.00 Mn |
| Sep 30, 2018 | 1.01 Mn |
| Sep 30, 2018 | 1.01 Mn |
| Jun 30, 2018 | 4.29 Mn |
| Jun 30, 2018 | 4.29 Mn |
| Dec 31, 2017 | 5.16 Mn |
| Dec 31, 2017 | 5.16 Mn |
| Dec 31, 2016 | 4.66 Mn |
| Dec 31, 2016 | 4.66 Mn |
| Sep 30, 2016 | 277,500.00 |
| Sep 30, 2016 | 277,500.00 |
| Jun 30, 2016 | 277,500.00 |
| Jun 30, 2016 | 277,500.00 |
| Mar 31, 2016 | 277,500.00 |
| Mar 31, 2016 | 277,500.00 |
| Dec 31, 2015 | 3.34 Mn |
| Dec 31, 2015 | 3.34 Mn |
| Sep 30, 2015 | 454,000.00 |
| Sep 30, 2015 | 454,000.00 |
| Jun 30, 2015 | 348,718.00 |
| Jun 30, 2015 | 348,718.00 |
| Mar 31, 2015 | 121,309.00 |
| Mar 31, 2015 | 121,309.00 |
| Sep 30, 2014 | 24,283.00 |
| Sep 30, 2014 | 24,283.00 |
| Jun 30, 2014 | 22,091.00 |
| Jun 30, 2014 | 22,091.00 |
| Mar 31, 2014 | 21,258.00 |
| Mar 31, 2014 | 21,258.00 |
| Dec 31, 2013 | 403,674.00 |
| Dec 31, 2013 | 403,674.00 |
| Sep 30, 2013 | 3.51 Mn |
| Sep 30, 2013 | 3.51 Mn |
| Jun 30, 2013 | 109,953.00 |
| Jun 30, 2013 | 109,953.00 |
| Mar 31, 2013 | 3.66 Mn |
| Mar 31, 2013 | 3.66 Mn |
| Dec 31, 2012 | 3.54 Mn |
| Dec 31, 2012 | 3.54 Mn |
| Sep 30, 2012 | 730,000.00 |
| Sep 30, 2012 | 730,000.00 |
| Jun 30, 2012 | 3.29 Mn |
| Jun 30, 2012 | 3.29 Mn |
| Dec 31, 2011 | 3.09 Mn |
| Dec 31, 2011 | 3.09 Mn |
| Dec 31, 2010 | 1.97 Mn |
| Dec 31, 2010 | 1.97 Mn |